Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".
University of California San Francisco, Department of Neurological Surgery, Neuro-Oncology Service, 400 Parnassus, Room A-808, San Francisco, California 94143-0372.
Michael D
MD
Prados
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D018318:Neurofibroma, Plexiform / Q000188:drug therapy*; D009456:Neurofibromatosis 1 / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D015363:Quinolones; D051231:Farnesyltranstransferase; C402769:tipifarnib